Expanded Potential Stem Cell lines of pig and human cells established
A new approach has enabled researchers to create Expanded Potential Stem Cells (EPSCs) of both pig and human cells. These stem cells have the features of the very first cells in the developing embryo, and can develop into any type of cell. The research from LKS Faculty of Medicine of The University of Hong Kong (HKUMed), the Wellcome Sanger Institute, and the Friedrich-Loeffler-Institut in Germany offers incredible potential for studying human development and regenerative medicine.
The study published in Nature Cell Biology today (3rd June) is the first time scientists have been able to derive stem cells from early pig embryos. Domestic pigs have great potential for biomedical research because of their genetic and anatomical similarities to humans, including comparable organ sizes. Being able to genetically-modify pig stem cells will also be beneficial for animal health and food production.
Stem cells have the ability to develop into other cell types, and existing stem cell lines are already extremely useful for research into development, disease and treatments. However, currently available types of stem cell lines have limitations, and until now it has also not been possible to create embryonic stem cells from pigs and many other farm animals.
“Scientists have been attempting to derive porcine embryonic stem cells for decades without much success. With our Expanded Potential Stem Cell technology, we have now successfully derived and characterised stem cells from porcine preimplantation embryos. We have also established similar human stem cells. Our study represents a significant advance in stem cell research.”
Professor Pentao Liu, the leader of the study from the School of Biomedical Sciences and Stem Cell and Regenerative Medicine Consortium, HKUMed, and previously of the Wellcome Sanger Institute
Since human EPSCs can produce large numbers of placenta cells – called trophoblasts – they offer new opportunities to investigate pregnancy complications such as pre-eclampsia and miscarriages.
EPSCs come from culturing cells from the earliest stage of development, when the fertilised egg has only divided into 4 or 8 cells and the cells retain some totipotency – the ability to produce all cell types.
“These EPSC stem cells possess developmental potency that is not generally seen in conventional embryonic or induced pluripotent stem cells. They have the potential to produce all embryonic and extra-embryonic cell lines – including those in the placenta and yolk sac, turning back the development clock to the very earliest cell type. These cells will enable researchers to study early embryonic development, miscarriage and developmental disorders.”
Dr Xuefui Gao, a first author on the paper from HKUMed, and previously from the Wellcome Sanger Institute
The first EPSCs were created in 2017, when the group targeted key molecular pathways during very early development in mice. At these very earliest embryonic developmental stages, mammalian species are very similar and the cells are like a blank sheet of paper. This study has shown that it is possible to use the same approach to create human EPSCs and also to establish EPSCs from pigs – mammals that had previously been elusive to stem cell researchers.
“Our porcine EPSCs isolated from pig embryos are the first well-characterized pig cell lines worldwide. EPSC’s great potential to develop into any type of cell provides important implications for developmental biology, regenerative medicine, organ transplantation, disease modelling, and screening for drugs.”
Dr Monika Nowak-Imialek, an author on the paper from the Friedrich-Loeffler-Institut (FLI) in Germany
The Latest on: Stem cells
via Google News
The Latest on: Stem cells
- VERIFY: Was the antibody cocktail used to treat President Trump developed using human embryonic stem cells?on October 7, 2020 at 6:51 pm
Social media is buzzing with the claim President Trump, who is pro-life, used an antibody cocktail developed using human embryonic stem cells.
- New biomarker may help identify patients at risk for graft-versus-host disease after stem cell transplantson October 7, 2020 at 5:13 pm
A recent report published in Science Translational Medicine by MUSC Hollings Cancer Center investigator Sophie Paczesny, M.D., Ph.D., sheds light on immune cell biomarkers that may reveal which ...
- New biomarker to prevent graft-versus-host disease in stem cell transplants discoveredon October 7, 2020 at 11:07 am
With more than $1.5 million in funding from the National Cancer Institute, MUSC Hollings Cancer Center researchers discovered a new biomarker, plasmacytoid dendritic cells expressing the ICOS ligand, ...
- Amniotic fluid stem cells may lead to better treatment for ischemic strokeon October 7, 2020 at 7:31 am
A study released today in STEM CELLS Translational Medicine points the way to a possible new avenue of treatment for ischemic stroke.
- Stem Cell Umbilical Cord Blood Market to Hit $10.13 Billion by 2027: AMRon October 7, 2020 at 6:41 am
As per the report published by Allied Market Research, the global Stem Cell Umbilical Cord Blood Market was pegged at $3.11 billion in 2019, and is projected to reach $10.13 billion by 2027, growing ...
- Matchis Foundation Improves Life-Saving Stem Cell Donation Processes with K2on October 7, 2020 at 5:37 am
K2, the leader in intelligent process automation, today announced that the Matchis Foundation, the Dutch center for stem cell donors, has implemented K2's ...
- Citius Pharma inks license pact with Novellus for stem cell therapy in respiratory distresson October 7, 2020 at 4:37 am
(NASDAQ:CTXR) has exercised its previously announced option agreement, and announced an exclusive agreement with Novellus Therapeutics to license iPSC-derived mesenchymal stem cells (iMSCs).The ...
- Stem Cell Daily News Service - ResearchAndMarkets.comon October 7, 2020 at 2:53 am
The "Stem Cell Daily" newsletter has been added to ResearchAndMarkets.com's offering. Stem Cell Daily includes the latest peer-reviewed research, patent filings, clinical trials, and policy ...
- Terahertz zaps alter gene activity in stem cellson October 5, 2020 at 4:38 am
Terahertz light pulses change gene expression in stem cells, report researchers from Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS) and Tokai University in Japan in the ...
- Cancer Stem Cells Market: Rapid Adoption of Stem Cells by Healthcare Professionals for Tissue Regeneration to Drive Marketon October 4, 2020 at 10:58 pm
Over the past couple of years, stem cells have found valuable use for replacement of blood after tumor formation or after tumor treatment. In addition, stem cell research has the capability to ...
via Bing News